Which has higher valuation and earnings, AGMB or ENLV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A

Is AGMB or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat AgomAb Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Enlivex Therapeutics N/A 248.08% 206.39%

Which has better earnings & valuation, RZLT or ENLV?

Rezolute is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A

Is RZLT or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Enlivex Therapeutics N/A 248.08% 206.39%

Does the media prefer RZLT or ENLV?

In the previous week, Rezolute had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Rezolute and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.25 beat Rezolute's score of -0.26 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, BNTC or ENLV?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A

Is BNTC or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Benitec Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% Enlivex Therapeutics N/A 248.08% 206.39%

Does the media prefer BNTC or ENLV?

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Benitec Biopharma. Enlivex Therapeutics' average media sentiment score of 0.25 beat Benitec Biopharma's score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Enlivex Therapeutics (ENLV) Competitors

$4.64 -0.04 (-0.85%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$4.60 -0.04 (-0.86%)

As of 08:43 AM Eastern

Compare

ENLV vs. AGMB, RZLT, EOLS, CCCC, and BNTC

Should you buy Enlivex Therapeutics stock or one of its competitors? MarketBeat compares Enlivex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enlivex Therapeutics include AgomAb Therapeutics (AGMB), Rezolute (RZLT), Evolus (EOLS), C4 Therapeutics (CCCC), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry.

How does Enlivex Therapeutics compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Enlivex Therapeutics' return on equity of 248.08% beat AgomAb Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Enlivex Therapeutics	N/A	248.08%	206.39%

AgomAb Therapeutics presently has a consensus price target of $32.75, indicating a potential upside of 173.37%. Enlivex Therapeutics has a consensus price target of $247.50, indicating a potential upside of 5,234.05%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

In the previous week, Enlivex Therapeutics had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 0 mentions for AgomAb Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.25 beat AgomAb Therapeutics' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AgomAb Therapeutics	Neutral
Enlivex Therapeutics	Neutral

Summary

Enlivex Therapeutics beats AgomAb Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Enlivex Therapeutics' return on equity of 248.08% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Enlivex Therapeutics	N/A	248.08%	206.39%

Rezolute currently has a consensus target price of $9.38, indicating a potential upside of 110.67%. Enlivex Therapeutics has a consensus target price of $247.50, indicating a potential upside of 5,234.05%. Given Enlivex Therapeutics' higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Rezolute is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

In the previous week, Rezolute had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Rezolute and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.25 beat Rezolute's score of -0.26 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Summary

Enlivex Therapeutics beats Rezolute on 7 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Evolus?

Evolus (NASDAQ:EOLS) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Enlivex Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Enlivex Therapeutics' return on equity of 248.08% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Enlivex Therapeutics	N/A	248.08%	206.39%

90.7% of Evolus shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Enlivex Therapeutics has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.23	-$51.64M	-$0.67	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

Evolus has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, Enlivex Therapeutics had 2 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 0 mentions for Evolus. Enlivex Therapeutics' average media sentiment score of 0.25 beat Evolus' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Evolus	Neutral
Enlivex Therapeutics	Neutral

Evolus presently has a consensus target price of $16.00, suggesting a potential upside of 188.29%. Enlivex Therapeutics has a consensus target price of $247.50, suggesting a potential upside of 5,234.05%. Given Enlivex Therapeutics' higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Enlivex Therapeutics beats Evolus on 10 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Enlivex Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	11.01	-$104.99M	-$1.19	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

C4 Therapeutics currently has a consensus target price of $7.75, indicating a potential upside of 116.48%. Enlivex Therapeutics has a consensus target price of $247.50, indicating a potential upside of 5,234.05%. Given Enlivex Therapeutics' higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Enlivex Therapeutics had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 0 mentions for C4 Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.25 beat C4 Therapeutics' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
C4 Therapeutics	Neutral
Enlivex Therapeutics	Neutral

C4 Therapeutics has a beta of 2.9, meaning that its share price is 190% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Enlivex Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Enlivex Therapeutics' return on equity of 248.08% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Enlivex Therapeutics	N/A	248.08%	206.39%

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Enlivex Therapeutics beats C4 Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Benitec Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Benitec Biopharma. Enlivex Therapeutics' average media sentiment score of 0.25 beat Benitec Biopharma's score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Benitec Biopharma is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

Enlivex Therapeutics' return on equity of 248.08% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Enlivex Therapeutics	N/A	248.08%	206.39%

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Benitec Biopharma currently has a consensus target price of $27.00, suggesting a potential upside of 125.56%. Enlivex Therapeutics has a consensus target price of $247.50, suggesting a potential upside of 5,234.05%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Enlivex Therapeutics beats Benitec Biopharma on 9 of the 13 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENLV vs. The Competition

Export

Metric	Enlivex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$78.77M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.56	20.20	27.07	23.95
Price / Sales	N/A	340.68	519.31	90.33
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.04	4.20	10.62	6.14
Net Income	$1.24B	$65.94M	$3.60B	$331.74M
7 Day Performance	-23.31%	-3.05%	-1.26%	-1.82%
1 Month Performance	-50.24%	-1.30%	1.07%	-1.45%
1 Year Performance	-74.01%	15.22%	23.63%	16.32%

Enlivex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENLV Enlivex Therapeutics	1.6576 of 5 stars	$4.64 -0.9%	$247.50 +5,234.1%	-74.0%	$78.77M	N/A	N/A	70	News Coverage
AGMB AgomAb Therapeutics	N/A	$13.28 -1.8%	$32.75 +146.6%	N/A	$481.23M	N/A	N/A	62
RZLT Rezolute	2.571 of 5 stars	$4.97 +0.8%	$9.38 +88.6%	-17.4%	$474.72M	N/A	N/A	40	News Coverage Positive News
EOLS Evolus	1.6617 of 5 stars	$6.94 -0.7%	$16.00 +130.5%	-39.7%	$460.33M	$297.18M	N/A	170
CCCC C4 Therapeutics	1.3329 of 5 stars	$4.35 +5.1%	$7.75 +78.2%	+54.3%	$457.75M	$35.95M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. AGMB, RZLT, EOLS, CCCC, and BNTC

How does Enlivex Therapeutics compare to AgomAb Therapeutics?

Summary

How does Enlivex Therapeutics compare to Rezolute?

Summary

How does Enlivex Therapeutics compare to Evolus?

Summary

How does Enlivex Therapeutics compare to C4 Therapeutics?

Summary

How does Enlivex Therapeutics compare to Benitec Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. AGMB, RZLT, EOLS, CCCC, and BNTC

How does Enlivex Therapeutics compare to AgomAb Therapeutics?

Do insiders and institutionals believe in AGMB or ENLV?

Is AGMB or ENLV more profitable?

Do analysts prefer AGMB or ENLV?

Which has higher valuation and earnings, AGMB or ENLV?

Does the media prefer AGMB or ENLV?

Summary

How does Enlivex Therapeutics compare to Rezolute?

Is RZLT or ENLV more profitable?

Do analysts recommend RZLT or ENLV?

Do institutionals & insiders believe in RZLT or ENLV?

Which has better earnings & valuation, RZLT or ENLV?

Does the media prefer RZLT or ENLV?

Which has more volatility & risk, RZLT or ENLV?

Summary

How does Enlivex Therapeutics compare to Evolus?

Is EOLS or ENLV more profitable?

Do institutionals and insiders hold more shares of EOLS or ENLV?

Which has higher earnings & valuation, EOLS or ENLV?

Which has more volatility and risk, EOLS or ENLV?

Does the media favor EOLS or ENLV?

Do analysts recommend EOLS or ENLV?

Summary

How does Enlivex Therapeutics compare to C4 Therapeutics?

Which has higher earnings & valuation, CCCC or ENLV?

Do analysts rate CCCC or ENLV?

Does the media prefer CCCC or ENLV?

Which has more risk and volatility, CCCC or ENLV?

Is CCCC or ENLV more profitable?

Do insiders and institutionals believe in CCCC or ENLV?

Summary

How does Enlivex Therapeutics compare to Benitec Biopharma?

Which has more volatility & risk, BNTC or ENLV?

Does the media prefer BNTC or ENLV?

Which has higher valuation and earnings, BNTC or ENLV?

Is BNTC or ENLV more profitable?

Do insiders & institutionals hold more shares of BNTC or ENLV?

Do analysts prefer BNTC or ENLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools